Regeneron Pharmaceuticals, Inc. (LON:0R2M)
606.40
+16.29 (2.76%)
At close: May 27, 2025
Regeneron Pharmaceuticals Employees
Regeneron Pharmaceuticals had 15,106 employees as of December 31, 2024. The number of employees increased by 1,656 or 12.31% compared to the previous year.
Employees
15,106
Change (1Y)
1,656
Growth (1Y)
12.31%
Revenue / Employee
719.24K GBP
Profits / Employee
229.74K GBP
Market Cap
47.42B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 15,106 | 1,656 | 12.31% |
Dec 31, 2023 | 13,450 | 1,599 | 13.49% |
Dec 31, 2022 | 11,851 | 1,483 | 14.30% |
Dec 31, 2021 | 10,368 | 1,245 | 13.65% |
Dec 31, 2020 | 9,123 | 1,023 | 12.63% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Regeneron Pharmaceuticals News
- 5 days ago - Does the 23andMe Acquisition Make Regeneron a Buy Now? - The Motley Fool
- 7 days ago - Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years - Benzinga
- 7 days ago - Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma - GlobeNewsWire
- 8 days ago - What Regeneron's Purchase Of 23andMe Means For Your Genetic Privacy - Forbes
- 8 days ago - Regeneron's 23andMe Steal: Smart Genetics Play That Won't Cure Near-Term Growth Pains - Seeking Alpha
- 9 days ago - Regeneron Pharmaceuticals, Inc. (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) - Seeking Alpha
- 9 days ago - 23andMe sale grafts a happy ending on to a glum tale - Financial Times
- 9 days ago - Viz.ai Announces Collaboration With Sanofi and Regeneron to Improve Management and Care of Chronic Obstructive Pulmonary Disease (COPD) - Business Wire